Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Due Nasdaq Warning Letter as Shares Close Below $1 for 30 Days

NEW YORK, March 31 (GenomeWeb News) - Transgenomic may receive a letter from the Nasdaq exchange today warning the firm that it may delist the company because its stock has closed below $1 per share for 30 consecutive trading days.

 

Shares in Transgenomic were flat at $.55 in mid-afternoon trading. The stock last closed above $1 on Feb. 14 when it reached $1.04.

 

According to Nasdaq rules, if Transgenomic receives such a warning letter the company will have 90 days to bring its share price above the $1 threshold, and keep it above that point for 10 days, or risk being downgraded to the small-capitalization Nasdaq market.

 

Officials from Transgenomic did not return a telephon calls seeking comment because the company is in a quiet period ahead of its fourth-quarter earning release and conference call, scheduled to take place at 5:00 p.m EST today.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.